Publication | Closed Access

A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer

Cell-based Drug DeliveryNanomedicineAntibody β-Lactamase ConjugateDrug TargetingMedicineCephalosporin-oncolytic ProdrugDrug Delivery SystemsTumor TargetingDrug Delivery SystemImmunotherapyPharmacologyRadiation OncologyDelivery System